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Abstract
Background: The protein kinase C (PKC) family comprises distinct classes of proteins, many of which are implicated
in diverse cellular functions. Protein tyrosine kinase C theta isoform (PRKCQ)/PKCθ, a member of the novel PKC
family, may have a distinct isoform-specific role in breast cancer. PKCθ is preferentially expressed in triple-negative
breast cancer (TNBC) compared to other breast tumor subtypes. We hypothesized that PRKCQ/PKCθ critically
regulates growth and survival of a subset of TNBC cells.
Methods: To elucidate the role of PRKCQ/PKCθ in regulating growth and anoikis resistance, we used both gain and
loss of function to modulate expression of PRKCQ. We enhanced expression of PKCθ (kinase-active or inactive) in
non-transformed breast epithelial cells (MCF-10A) and assessed effects on epidermal growth factor (EGF)-
independent growth, anoikis, and migration. We downregulated expression of PKCθ in TNBC cells, and determined
effects on in vitro and in vivo growth and survival. TNBC cells were also treated with a small molecule inhibitor to
assess requirement for PKCθ kinase activity in the growth of TNBC cells.
Results: PRKCQ/PKCθ can promote oncogenic phenotypes when expressed in non-transformed MCF-10A
mammary epithelial cells; PRKCQ/PKCθ enhances anchorage-independent survival, growth-factor-independent
proliferation, and migration. PKCθ expression promotes retinoblastoma (Rb) phosphorylation and cell-cycle
progression under growth factor-deprived conditions that typically induce cell-cycle arrest of MCF-10A breast
epithelial cells. Proliferation and Rb phosphorylation are dependent on PKCθ-stimulated extracellular signal-related
kinase (Erk)/mitogen-activated protein kinase (MAPK) activity. Enhanced Erk/MAPK activity is dependent on the
kinase activity of PKCθ, as overexpression of kinase-inactive PKCθ does not stimulate Erk/MAPK or Rb
phosphorylation or promote growth-factor-independent proliferation. Downregulation of PRKCQ/PKCθ in TNBC cells
enhances anoikis, inhibits growth in 3-D MatrigelTM cultures, and impairs triple-negative tumor xenograft growth.
AEB071, an inhibitor of PKCθ kinase activity, also inhibits growth and invasive branching of TNBC cells in 3-D
cultures, further supporting a role for PKCθ kinase activity in triple-negative cancer cell growth.
Conclusions: Enhanced PRKCQ/PKCθ expression can promote growth-factor-independent growth, anoikis
resistance, and migration. PRKCQ critically regulates growth and survival of a subset of TNBC. Inhibition of PKCθ
kinase activity may be an attractive therapeutic approach for TNBC, a subtype in need of improved targeted
therapies.
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Background
Triple-negative breast cancer (TNBC) represents ap-
proximately 15 % of all breast cancer and is a subtype
for which therapeutic options are more limited due to
lack of effective targeted therapies. Triple-negative breast
cancer is defined by the lack of expression of estrogen
receptor (ER), progesterone receptor (PR), and human
epidermal growth factor receptor 2 (Her2), but it is gen-
etically and genomically diverse. Due to the lack of tar-
geted therapies and intrinsic biological aggressiveness,
novel therapeutic strategies, beyond standard-of-care
chemotherapy, are desperately needed.
We first identified protein tyrosine kinase C theta iso-
form (PRKCQ)/PKCθ as a candidate regulator of
anchorage-independent survival of breast cancer cells in
a functional kinome screen [1]. PRKCQ/PKCθ is a mem-
ber of the novel protein kinase C (PKC) family charac-
terized by a unique protein domain structure consisting
of diacylglycerol binding sites, but lacking calcium (Ca+)
binding sites typical of classical PKCs. PRKCQ maps to
Chromosome 10p15, a region frequently mutated in T
cell leukemia, lymphoma and T cell immunodeficiency
(as reviewed in [2]). PRKCQ/PKCθ is widely expressed
throughout the hematopoietic system, primarily in T
cells, mast cells, natural killer (NK) cells and platelets,
and in skeletal muscle, liver, thymus, and the nervous
system [3–6].
Much of the known isoform-specific functions of
PRKCQ/PKCθ are in the context of immune function;
mice deficient in PRKCQ expression exhibit defects in
T cell activation due to impaired Ca+ signaling and
nuclear factor of activated T cells (NFAT) activation
[7, 8]. PRKCQ/PKCθ also regulates the survival of T
cells by regulating the expression of pro-apoptotic
and anti-apoptotic B cell lymphoma 2 (Bcl2) family
members [2, 8, 9]. More recent evidence supports a
relative specific role for PRKCQ in immune response;
it is mostly dispensable for immunity against viral
and bacterial pathogens [2, 10–12]. In contrast,
PRKCQ appears to be required for immune responses
associated with autoimmune disease and allograft re-
jection, perhaps due to a specific requirement for
PRKCQ in the maturation of T helper (Th)17 cells, a
subset of CD4+ T cells [13–16].
In contrast, the functions of PRKCQ in non-
hematopoietic tissue and in cancer have not yet been
fully elucidated. PRKCQ is reported to be expressed
in solid tumors including gastrointestinal stromal tu-
mors (GIST) and more recently, in breast cancer, spe-
cifically ER-negative tumors [17–20]. In fact, PRKCQ
expression directly suppresses the expression of ERα
in breast cancer cells and is required for c-rel-
induced mammary tumorigenesis [20]. PRKCQ also
stimulates breast cancer cell migration by stabilizing
the expression of Fra-1 in TBNC cells [21]. Further-
more, PRKCQ may contribute to the formation or
maintenance of a breast cancer stem cell population
by promoting the expression of genes associated with
epithelial-mesenchymal transition (EMT) through dir-
ect chromatin interactions [22, 23].
The role of PRKCQ/PKCθ in the proliferation and sur-
vival of breast cancer cells and the responsible mechanisms,
including dependency on kinase activity, remain to be clari-
fied. Here we show that PRKCQ is sufficient to drive
growth-factor-independent proliferation, migration and
anoikis resistance of breast epithelial cells (MCF-10A).
PRKCQ promotes proliferation by activating extracellular
signal-related kinase (Erk)/mitogen-activated protein kinase
(MAPK) activity in a kinase-activity-dependent manner.
PRKCQ is not only sufficient to promote these phenotypes
in MCF-10A cells, but, we showed for the first time that it
is required for in vitro and in vivo growth of a subset of
TNBC cells. These studies support PRKCQ/PKCθ as an at-
tractive candidate therapeutic target in TNBC.
Methods
Reagents, cells, and cell culture
MDA-MB-231-luc-D3H2LN cells were obtained from
Perkin Elmer. Cells were cultured in MEM with Earle’s
Salts supplemented with non-essential amino acids, Glu-
taMAX™, sodium pyruvate, penicillin/streptomycin (P/S;
Life Technologies) and 10 % heat-inactivated fetal bovine
serum (FBS) (Life Technologies) at 37 °C in 5 % CO2.
All other cell lines were purchased from ATCC (Manas-
sas, Virginia). MDA-MB-436 cells were cultured in
Leibovitz’s L-15 media supplemented with 10 ug/mL in-
sulin, 16 ug/mL glutathione, P/S, and 10 % FBS at 37 °C
under atmospheric conditions. MCF10A cells were cul-
tured in 1:1 DMEM/F12 supplemented with 5 % horse
serum, 20 ng/mL EGF (Peprotech), 500 ug/mL hydro-
cortisone (Sigma-Aldrich), 100 ng/mL cholera toxin
(Sigma-Aldrich), 10 ug/mL insulin (Sigma-Aldrich), and
penicillin/streptomycin (Life Technologies). HCC1806
and HCC38 cells were cultured in RPMI-1640 media
supplemented with 10 % FBS and P/S. AEB071 was
purchased from Selleckchem.
Antibodies directed against the following proteins were
obtained from the indicated suppliers: AbCam: rabbit
monoclonal protein kinase C (PKC-θ) (EPR1487(2)); Cell
Signaling Technologies: phospho-retinoblastoma (Rb)
(S807/811) and total Rb, phospho-p44/p42 MAPK (ERK1/
2) (T202/Y204) and total p44/42 MAPK (ERK1/2),
phospho-Akt (S473) and total (pan-) Akt, PKC isoform
antibody sampler kit (for PKCδ, PKCα, PKCμ, PKCζ)
phospho-PKCθ (T538), phospho-PKCα/βII (T638/641),
glyceraldehyde-3-phosphate dehydrogenase (GAPDH),
and beta-tubulin. Additional GAPDH antibody from Santa
Cruz Biotechnology was used.
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Constructs, viral production, and stable cell line
generation
PRKCQ complementary DNA (cDNA) encoding retro-
viral vector was obtained from Joshua LaBaer (Harvard
Institute of Proteomics). Mutagenesis to create PRKCQ
mutants was performed using QuikChange Lightning
Site-Directed Mutagenesis Kit (Stratagene) and the fol-
lowing primers: 5′ GCATCAGCGCCGGGGTGAAAT
CAAGCAGGCAAAGGTC-3′ for A148E (constitutively
active) and 5′ CCAATCAATTTTTCGCAATAAGGGC
CTTAAAGAAAGATGTGG-3′ for K409R (catalytically
inactive) [24]. Retrovirus was generated using 293-GPG
cells (gift of R. Mulligan) and according to protocols de-
scribed previously [25].
Constructs encoding short hairpin RNA (shRNA)
sequences targeting PRKCQ (TRCN0000001790,
TRCN0000199654 and TRCN0000197216, referred to as
90, 54 and 16, respectively) were purchased from Open
Biosystems/Thermo Scientific. Viral packaging 293 T
cells were transfected according to standard protocols to
produce lentiviral particles, as described previously [25].
Viral supernatant was collected 24, 48, 72, and 96 hours
post-transfection, pooled, and concentrated using Ami-
con Ultra Centrifugal Filter Units (Millipore). MDA-
231-luc or MDA-436 cells were spin-infected in the
presence of 2 ug/mL polybrene (Sigma-Aldrich) and
concentrated viral supernatant at 2250 rpm for 30 mi-
nutes. Cells were exposed to viral supernatant overnight
before changing to complete media and were allowed to
recover for 24 hours.
Anoikis and transwell migration assays
Anoikis (anchorage-independent viability) assay was per-
formed by culturing cells in suspension on polyhema-
coated plates for the indicated amount of time, and cell
death was assessed using the Cell Death ELISAPLUS Kit
(Roche) according to manufacturer’s instructions. Trans-
well migration assay was performed as described previ-
ously [25].
Proliferation assay/growth curves
Cells were plated at a density of 1 × 10^4 cells per well
in triplicate in a 24-well plate. Cells were harvested and
counted using a hemacytometer at the indicated number
of days after seeding.
3-D culture
Three-dimensional (3-D) Matrigel™ (BD Biosciences)
cultures were performed as described previously using
3000–5000 cells/well [25].
Cell cycle analysis/flow cytometry
Cells were plated at subconfluent densities, harvested
using 0.05 % Trypsin/EDTA (Life Technologies), washed
with PBS, resuspended as single cells in cold PBS and
fixed with ice-cold ethanol at a final concentration of
70 %. After fixation cells were stored at 4 °C until stain-
ing. Cells were stained using propidium iodide (PI)/
RNase Staining Buffer (BD Biosciences) at 37 °C for
30 minutes before sample processing. DNA content was
assessed by PI staining using BD Canto and FACSDiva.
Cell cycle profiles were analyzed using Flow Jo (version
9.0). Percentages were calculated using the Watson prag-
matic algorithm. Significance was calculated using the
standard Student t test.
In vivo tumor xenograft models
Female nude mice (nu-/-) were obtained from Jackson La-
boratories. At age 6–8 weeks, 5 × 10^5 MDA-231-luc cells
per mouse were injected subcutaneously in a total volume
of 100 uL of complete media 48 hours after infection with
PRKCQ shRNA lentiviral particles. Tumor dimensions
were measured with calipers and the volume was calcu-
lated as (L x W2)/2. Stastical significance was calculated
using the Whitney-Mann-Wilcoxon rank sum test. All
procedures and studies with mice were performed in ac-
cordance with protocols pre-approved by the Institutional
Animal Care and Use Committee of Mount Sinai.
PRKCQ transcript expression analysis in breast tumors
The Cancer Genome Atlas (TCGA) dataset
Level-3 expression IlluminaHiSeq-RNASeqV2 expres-
sion data were downloaded from the TCGA data por-
tal [26] and processed for quality control as follows:
log(x + 1) transformation was performed to rescale the
expression data, followed by quantile-normalization,
using normalize.quantiles() from R package “prepro-
cessCore”. The quantile-normalized data were split for
tumor and normal tissue samples. Correction for
batch effects was performed using batch ID, tissue
source site ID, center ID and plate ID, where batch
ID was obtained from TCGA biospecimen files, and
other IDs were obtained from TCGA barcode. Batch
and age corrections were performed using the linear
regression (lm()) function in the statistical computing
software R, for each gene expression profile, thereby
removing discrepancy between different batch IDs,
and preserving the overall mean across all samples.
Expression of PRKCQ was then extracted and patients
were classified as receptor positive (ER, PR, or Her2
positive, n = 731) or TNBC (ER, PR, and Her2 nega-
tive, n = 86). The significance of difference in log
expression was tested using the one-sided Student t
test.
METABRIC dataset
METABRIC-normalized Illumina HT12v3 data were
downloaded from the European Bioinformatics Institute,
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quantile-normalized, and corrected for age [27]. Samples
were stratified as TNBC or receptor-positive as follows:
samples with negative expression of ER, PR, and Her2,
as reported by Curtis et al. [27] in the columns
“ER.Expr,” “PR.Expr”, and “Her2.Expr,” respectively, and
not classified as luminal A, luminal B, or Her2 by
PAM50 subtyping, also reported by Curtis et al. [27],
were labeled TNBC (n = 276); all other samples were la-
beled receptor-positive (n = 1698). PRKCQ expression
was extracted and log expression was compared in the
TNBC and receptor-positive samples using the one-
sided Student t test.
Consent statement
We confirm that this study does not involve human pa-
tients and no consent was necessary.
Results
PRKCQ is sufficient to promote anoikis resistance,
migration and growth factor-independent proliferation
During tumorigenesis, cells often acquire the ability
to survive and grow in conditions (e.g., matrix or
growth factor deprivation) that do not support
proliferation of normal cells. For example, non-
transformed, immortalized MCF10A breast epithelial
cells are highly dependent on the presence of growth
factors (e.g., insulin and EGF) for cell division and
growth; absence of these growth factors in the culture
medium induces cell-cycle arrest ([28] and Fig. 1d).
To determine whether PRKCQ/PKCθ is sufficient to
promote oncogenic activity, such as growth factor-
independent growth, we expressed PRKCQ in MCF-
10A cells, which express relatively low levels of basal
PRKCQ. When overexpressed in MCF-10A cells,
Fig. 1 Protein tyrosine kinase C theta isoform (PRKCQ) overexpression promotes multiple oncogenic activities in breast epithelial cells. a Non-
transformed, immortalized MCF-10A cells overexpressing vector control or PRKCQ were generated, and assessed for their ability to survive in
suspension cultures using the Cell Death ELISA assay. b The ability of MCF-10A cells overexpressing vector control or PRKCQ in Transwell Boyden
chamber assays in the presence or absence of epidermal growth factor (EGF) was evaluated. The number of cells that migrated 18 hours after
plating in the insert was counted. Five fields of migrated cells (×10 objective) were counted and averaged. c MCF-10A cells expressing vector
control or PRKCQ (1 × 10^4 cells) were plated on day 1 in growth media lacking EGF. The number of cells were counted on the indicated days
and plotted. d Cell-cycle profile analysis of empty vector or PRKCQ-expressing cells was performed by fluorescence-activated cell sorting after
propidium iodide staining of cells cultured in growth media +/- EGF: *p < 0.05, **p < 0.01, ***p < 0.001. PKC protein kinase C
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PRKCQ suppresses anoikis in suspension cultures
(Fig. 1a) and enhances EGF-independent migration in
Transwell assays (Fig. 1b). Furthermore, PRKCQ pro-
motes EGF-independent growth in monolayer cul-
tures; this is due to the ability of PRKCQ to partially
prevent G1 arrest and promote cell-cycle progression
in the absence of EGF stimulation (Fig. 1c and d).
Therefore, PRKCQ is sufficient to enhance EGF-
independent growth, anoikis resistance and migration
of non-transformed MCF-10A breast epithelial cells.
PRKCQ enhances EGF-independent growth by activating
Erk/MAPK and Rb phosphorylation in a kinase activity-
dependent manner
We sought to determine the mechanisms by which
PRKCQ expression promotes cell-cycle progression
under conditions that typically induce G1 cell cycle ar-
rest of MCF-10A cells (e.g., EGF deprivation). Cells over-
expressing PRKCQ/PKCθ exhibit enhanced levels of Rb
phosphorylation when compared to vector control cells
cultured in media lacking EGF. We examined the status
Fig. 2 Extracellular signal-related (Erk)/mitogen-activated protein kinase (MAPK) activation is required for protein tyrosine kinase C theta isoform
(PRKCQ)-mediated epidermal growth factor (EGF)-independent growth. a MCF-10A cells overexpressing pBabe vector control or wild-type PRKCQ
were cultured in growth media lacking EGF. Lysates were probed with the indicated antibodies. b PRKCQ or vector control expressing MCF-10A
cells were cultured in growth media +/- EGF. Cells grown in the absence of EGF were treated for 24 hours with dimethyl sulfoxide (DMSO) or
mitogen-activated protein kinase kinase (MEK) inhibitor U0126 (5 μM). Cells were lysed and probed with the indicated antibodies. c MCF-10A cells
expressing vector control or PRKCQ were cultured in growth media lacking EGF and treated with DMSO or U0126 (5 μM) for the indicated
number of days. DMSO or U0126 was replaced every 2–3 days. Cell numbers were counted on the indicated days and plotted. Rb retinoblastoma
Byerly et al. Breast Cancer Research  (2016) 18:95 Page 5 of 11
of signaling pathways linked to cell-cycle progression
and proliferation. Levels of activated Erk/MAPK, but not
Akt, were increased in PRKCQ-overexpressing cells.
(Fig. 2a). Erk/MAPK activity is required for PRKCQ-
stimulated Rb phosphorylation and cell-cycle progres-
sion under EGF-deprived conditions; treatment of
PRKCQ-overexpressing cells with U0126, an inhibitor of
MAPK kinase (MEK), abrogated the increased Rb phos-
phorylation and the EGF-independent growth promoted
by PRKCQ expression (Fig. 2b and c).
To determine if PRKCQ-stimulated Erk/MAPK activ-
ity, Rb phosphorylation, and cell-cycle progression are
dependent on PRKCQ kinase activity, we generated both
constitutively active (A148E) and kinase inactive
(K409R) versions of PKCθ [24]. Overexpression of
kinase-active PKCθ enhanced Erk/MAPK activity, Rb
phosphorylation and EGF-independent growth, whereas
overexpression of kinase-inactive PKCθ did not (Fig. 3a,
b). These results support a critical role for kinase activity
in PRKCQ-stimulated, EGF-independent Erk/MAPK ac-
tivity, Rb phosphorylation and cell-cycle progression in
MCF-10A cells.
PRKCQ is preferentially expressed in TNBC
We examined the level and pattern of expression of
PRKCQ in patients’ breast tumors. Among tumors in
TCGA dataset, PRKCQ transcript levels are higher in
triple-negative tumors (e.g., negative for expression of
ER, PR or Her2), when compared to tumors that express
ER, PR and/or Her2 (p = 8.61 × 10^-9) (Fig. 4a). A simi-
lar pattern of higher PRKCQ transcript expression in
patients’ triple-negative tumors compared to receptor-
positive tumors was observed in the larger METABRIC
dataset, which consists of nearly 2000 patient tumors
(Fig. 4b). This expression pattern for PRKCQ is in agree-
ment with a previous study that reported higher levels of
PRKCQ transcript expression in ER-negative breast can-
cers when compared to ER-positive tumors, using other
publicly available datasets [20]. This pattern of expres-
sion is also reflected in a panel of breast cancer cell lines
that represent distinct breast cancer subtypes. Expres-
sion of PKCθ protein was detected in a subset of triple-
negative, basal breast cancer cell lines, whereas ER-
positive/luminal and Her2-positive breast cancer cell
lines express none to barely detectable levels of PKCθ
protein (Fig. 4c). Other novel PKC isoforms such as
PKCδ did not have a similar differential expression pat-
tern (Fig. 4c).
Inhibition of PRKCQ impairs in vitro and in vivo growth of
TNBC cells
To begin to address the requirement for PRKCQ/PKCθ
expression for growth and survival of TNBC cells, we
downregulated its expression in cell lines with detectable
levels of PKCθ protein (MDA-231-LucD3H2LN, MDA-
436, HCC38, and HCC1806 cells) using several inde-
pendent shRNA vectors (Fig. 5a). shRNA vectors that
specifically downregulated expression of PKCθ, with
minimal effect on expression of other PKC family mem-
bers were chosen for functional studies. For the
HCC1806 cell line, PRKCQ shRNA vector 16 was used,
as vectors 90 and 54 resulted in significant downregula-
tion of other PKC isoforms (Fig. 5a and unpublished
data). In all cell lines evaluated, PKCθ protein downreg-
ulation severely compromised growth in 2-D monolayer
cultures (Fig. 5b). The growth inhibition was consistent
Fig. 3 Protein tyrosine kinase C theta isoform (PRKCQ) kinase activity is required for epidermal growth factor (EGF)-independent growth,
Extracellular signal-related kinase (Erk activity) and retinoblastoma (Rb) phosphorylation. a MCF-10A cells expressing vector control, constitutively
active (A148E) or kinase-inactive (K409R) PKCθ, were cultured in growth media lacking EGF. Cell lysates were probed with the indicated antibodies.
b MCF-10A cells expressing vector control, active or kinase-dead PKCθ, were cultured in media lacking EGF for the indicated number of days
and counted
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with arrest in the G2-M transition (Additional file 1:
Figure S1). PKCθ downregulation in these TNBC cells
also enhanced anoikis in suspension cultures (Fig. 5c). In
3-D Matrigel™ cultures, PKCθ downregulation inhibited
growth, and the formation of invasive branches charac-
teristic of TNBC cell lines (Fig. 5d). Importantly, infec-
tion of MDA-231 cells, which have undetectable levels
of PKCθ protein, with PRKCQ-targeting shRNA viral
supernatant, did not inhibit their growth in 3-D cultures
(Additional file 1: Figure S2).
Consistent with the phenotypes observed in the in
vitro cultures, PRKCQ/PKCθ downregulation impaired
growth of triple-negative breast primary tumor xeno-
grafts (Fig. 5e). Downregulation of PKCθ in MDA-
231-Luc-D3H2LN cells using two independent shRNA
vectors (90 and 54) inhibited growth of primary
tumor xenografts following subcutaneous injection
into the flanks of nude mice. These data show for the
first time that endogenous PRKCQ is necessary for
the in vivo growth of human TNBC, and that PRKCQ
plays a unique role that is not redundant with those
of other PKC isoforms.
Several PKC inhibitors have been developed. Although
none are currently completely specific for PRKCQ/
PKCθ, AEB071 has demonstrated selective activity
against novel and classic PKC family members [29]. We
confirmed that treatment of MDA-231-Luc-D3H2LN
cells with AEB071 inhibited PKCθ autophosphorylation
at Threonine 538, even at doses as low as 100 nM
(Fig. 6a). In contrast, AEB071 treatment of TNBC cells
at the doses evaluated did not affect the activity of
PKCα/β2, both classic PKC’s, as assessed by autophos-
phorylation at Threonine 638/641 (Fig. 6a). Treatment
of MDA-231-Luc-D3H2LN cells with AEB071 impaired
growth in 3-D MatrigelTM cultures and prevented inva-
sive branching at doses that inhibit PKCθ autophospho-
rylation, thus phenocopying the effects of PRKCQ
shRNA expression (Fig. 6b). These data further support
the importance of PKCθ kinase activity in the oncogenic
activity of TNBC cells, and the potential for clinical
Fig. 4 Protein tyrosine kinase C theta isoform (PRKCQ) is preferentially expressed in the triple-negative breast cancer (TNBC) subtype and breast
cancer cell lines. PRKCQ transcript levels in triple-negative and hormone-receptor-positive or human epidermal growth factor (Her2)-positive
patient tumors in The Cancer Genome Atlas dataset (TCGA) (a) and METABRIC dataset (b) were compared. c PKCθ protein expression in breast
cancer cell lines was assessed by western analysis. Expression of PRKCδ, another novel PKC isoform, was also examined. GAPDH
glyceraldehyde-3-phosphate dehydrogenase
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Fig. 5 (See legend on next page.)
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translation of PKCθ kinase inhibitors as a therapeutic
option for patients with TNBC.
Discussion
The functions of PKC family members are varied and di-
verse. PKC expression or activity is detected in cancer
cells and for this reason, inhibitors of the PKC family
have been developed and evaluated as potential cancer
therapeutic agents. However, their use in cancer therapy
has been limited. One potential reason may be the lack
of biomarkers and the potential isoform-specific func-
tions of PKC enzymes. While many of the PKC enzymes
are associated with pro-tumorigenic activities, there is
also evidence that supports possible tumor-suppressive
roles for some PKC family members. For example, muta-
tions detected in PKC enzymes in patient tumors have
been reported to have growth-inhibitory properties in
vitro [30]. Therefore, the precise functions of specific
PKC isoforms in human cancer need to be clearly eluci-
dated for optimal development of PKC isoform-targeted
therapeutic agents.
PRKCQ/PKCθ has been extensively studied in the con-
text of hematopoiesis and immunity, and is required for
the development and maturation of specific T cell sub-
sets. PRKCQ also plays a role in Notch-driven T cell
leukemia [31]. However, its function in epithelial cancer
has been relatively underexplored. PRKCQ is expressed
or activated in a subset of GIST, uveal melanoma, and
breast cancers [17, 19, 20, 32]. Here, we show that
PRKCQ is sufficient to promote oncogenic activities
such as anoikis resistance and growth-factor-
independent migration and proliferation. Our studies are
also the first to demonstrate the isoform-specific re-
quirement for endogenous PRKCQ in the in vitro and in
vivo growth of a subset of human TNBC cell lines.
PRKCQ/PKCθ expression is relatively greater in human
triple-negative tumors compared to other subtypes, fur-
ther supporting PRKCQ/PKCθ as a candidate thera-
peutic target for this subtype.
Our studies highlight the critical role of PKCθ kinase
activity in tumorigenic phenotypes; kinase activity is re-
quired to enhance growth-factor-independent cell-cycle
progression of MCF-10A cells via Erk/MAPK activity
and Rb phosphorylation, and inhibition of PKCθ kinase
activity impairs the growth and invasiveness of TNBC
cells. These results support the possibility of targeting
(See figure on previous page.)
Fig. 5 Protein tyrosine kinase C theta isoform (PRKCQ) downregulation inhibits growth of triple-negative breast cancer (TNBC) cells in culture and
triple-negative breast tumor xenografts. a Lentiviral PRKCQ short hairpin (sh)RNA vector-infected TNBC cells were lysed and probed for expression of
protein kinase C (PKC) family members. b TNBC cells expressing empty vector control (EV) or PRKCQ shRNA (90, 54 or 16) were grown in monolayer
cultures for the indicated number of days and counted. c TNBC cells expressing vector control or PRKCQ shRNA (90, 54 or 16) were cultured in
suspension for 24 hours. Cell death (anoikis) was assessed using the Cell Death ELISA. d TNBC cells expressing EV control or PRKCQ shRNA vectors
were cultured in 3-D MatrigelTM cultures in chamber slides for the indicated number of days. e MDA-231-Luc-D3H2LN cells (5 × 105) expressing vector
control or PRKCQ shRNA (90 or 54) were injected subcutaneously into the flank of 6-week-old, female nude mice. Tumor size was measured and
recorded every 3–4 days. All figures are representative of three independent experiments except for the xenograft study, which was performed twice.
Scale bars represent 200 μM. GAPDH glyceraldehyde-3-phosphate dehydrogenase
Fig. 6 Treatment with AEB071 inhibits protein kinase C (PKC)θ activity and impairs growth of triple-negative breast cancer cells. a MDA-231-Luc-
D3H2LN cells were treated with AEB071 at the indicated concentrations for 24 hours. Cells were lysed and probed with antibodies that recognize
autophosphorylated PKC isoforms. b MDA-231-Luc-D3H2LN cells were treated with the indicated concentrations of AEB071 in 3-D Matrigel™
cultures for 7 days with refeeding every 2–3 days. Scale bar indicates 200 μM. DMSO dimethyl sulfoxide
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PRKCQ kinase activity as a therapeutic approach for a
subset of TNBC.
Although our studies are the first to show a critical
role for endogenous PRKCQ in the growth and survival
of a subset of human TNBC cells, our data complement
previous work that suggested a role for PRKCQ in ER-
negative breast cancers. Belguise et al. report that
PRKCQ suppresses ER transcription via Akt activation
and Forkhead inhibition, and PRKCQ is required for c-
Rel-driven, ER-negative development of a mouse mam-
mary tumor [20]. PRKCQ also promotes the stabilization
of Fra-1, a member of the Fos transcription factor family
in ER-negative breast cancer [21].
Interestingly, in addition to its role in regulating sig-
naling in ER-negative breast cancer, PRKCQ has been
shown to localize to the nucleus where it directly inter-
acts with chromatin complexes to induce expression of
genes associated with an epithelial-to-mesenchymal
transition, and markers associated with a cancer stem
cell phenotype [23]. Kinase activity of PKCθ was re-
quired for this induction of mesenchymal gene expres-
sion. These data and our own results showing the
kinase-activity-dependent activation of Erk/MAPK sig-
naling by PRKCQ highlight the potentially multiple ways
by which PRKCQ kinase activity may promote onco-
genic activity in TNBC cells via signaling and transcrip-
tional mechanisms in specific subcellular compartments.
The recent synthesis of PRKCQ/PKCθ small molecule
kinase inhibitors raises the attractive possibility of using
these to therapeutically target PRKCQ in TNBC. These
inhibitors are highly specific for PRKCQ, relative to
other PKC isoforms, and have been developed for the
treatment of autoimmune or inflammatory disease [33].
The kinase dependency of PRKCQ oncogenic activity
supports the evaluation of these inhibitors in the context
of breast cancer models. Given the expression of
PRKCQ in the cells of the immune system, the effect of
PRKCQ inhibition on host immunity must be consid-
ered. However, as PRKCQ-/- mice appear to maintain
normal immune responses to most bacterial and viral
pathogens, it is unlikely that PRKCQ inhibition will sig-
nificantly compromise the host defense mechanisms
reviewed in [2]. Interestingly, PRKCQ is specifically re-
quired for the maturation and development of Th17
cells, which have been implicated in autoimmune dis-
eases, such as multiple sclerosis and arthritis [14, 15].
Although the role of Th17 cells in cancer development
or progression is controversial, IL-17 and other cyto-
kines secreted by Th17 T cells have been shown to pro-
mote tumorigenesis [34]. The use of these isoform-
specific PRKCQ inhibitors could provide unique insights
into the interaction between triple-negative tumor cells,
their immune microenvironment and systemic immune
responses.
Conclusions
Our studies support PRKCQ/PKCθ as a therapeutic tar-
get for TNBC. Enhanced PRKCQ expression is sufficient
to promote anoikis resistance, migration, and EGF-
independent growth via kinase-activity-dependent stimu-
lation of Erk/MAPK. Inhibition of PRKCQ, either by
downregulation of expression or inhibition of kinase ac-
tivity, suppresses TNBC growth, highlighting the poten-
tial of PRKCQ small molecule inhibitor treatment as a
therapeutic strategy.
Additional file
Additional file 1: Figure S1. PRKCQ downregulation in MDA-231-
LucD3H2LN cells results in G2-M arrest. Triple-negative MDA-231-
LucD3H2LN cells were infected with PRKCQ shRNA lentiviral supernatant
for 48 hours. Cells were fixed and stained with PI, and cell-cycle
profile analysis was performed using flow cytometry. Results from four
independent experiments were averaged. Figure S2 PRKCQ shRNA has
no effect on growth of MDA231 cells that do not express detectable
PKCθ protein. MDA231 cells expressing empty vector (EV) or PRKCQ
shRNA (54) were grown in 3-D cultures for 7 days. (PDF 573 kb)
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